Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices, which comprise these compounds.

Abstract: A method of synthesizing carboxyl-modified molybdenum disulfide comprises the steps of a) preparing a molybdenum disulfide solution; b) adding hydrogen bromide (HBr) to the molybdenum disulfide solution, followed by blending the mixture; and c) adding oxalic acid (OA) to the molybdenum disulfide solution, followed by blending the mixture. The molybdenum disulfide synthesized by the method is applicable to a biosensing chip. The carboxyl-modified molybdenum disulfide effectively enhances sensitivity of a detection device having the biosensing chip.

Abstract: The present disclosure provides a single-side modified ?-Anderson-type heteropolymolybdate organic derivative having an anionic moiety with a general formula represented by: ?-{[RC(CH2O)3]M(OH)3Mo6O18}3?; ? represents a non-planar folded structure; R=substituted or unsubstituted phenyl, CnH2nX (n is an integer from 0 to 22; X=H, OH, NH(CH2)3SO3H, NHCH2COOH, NH2, or NO2); M=Cr3+. The single-side modified ?-Anderson-type heteropolymolybdate organic derivative can be prepared under hydrothermal conditions.

Abstract: The present invention provides an iridium compound useful as a raw material compound for producing a cyclometalated iridium complex, the iridium compound being represented by the following General Formula (1). The iridium compound of the present invention is particularly useful as a raw material for imidazole-based cyclometalated iridium complexes among cyclometalated iridium complexes. (In General Formula (1), Ir represents an iridium atom, O represents an oxygen atom, X represents a halogen atom, and Y represents a counter cation; and R1 and R2 each independently represent an alkyl group with a carbon number of 1 or more and 10 or less, with the proviso that only one of R1 and R2 is a branched alkyl group.

Abstract: An organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound:

Abstract: A binder comprising a polymeric binder comprising the products of a carbohydrate reactant and nucleophile is disclosed. The binder is useful for consolidating loosely assembled matter, such as fibers. Fibrous products comprising fibers in contact with a carbohydrate reactant and a nucleophile are also disclosed. The binder composition may be cured to yield a fibrous product comprising fibers bound by a cross-linked polymer. Further disclosed are methods for binding fibers with the carbohydrate reactant and polyamine based binder.

Abstract: The purpose of the present invention is to determine the structure of a novel steviol glycoside that is detected in cultivers containing an abundance of Reb.C (also called dulcoside B) and that affects the quality of taste in a small amount, and to identify the quality of taste properties. According to the present invention, a compound represented by formula (1), or a derivative, salt, or hydrate thereof is provided.

Abstract: The present invention relates to inorganic salts of nicotinic acid mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, M1, M2, k, R1, R2, and R3 are as described herein.

Abstract: The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(?-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.

Abstract: Embodiments of the present disclosure relate to methods of preparation of templates for polynucleotide sequencing. In particular, the disclosure relates to linearization of clustered polynucleotides in preparation for sequencing by cleavage of one or more first strands of double-stranded polynucleotides immobilized on a solid support by a transition metal complex, for example, a palladium complex or a nickel complex. Further disclosure relate to linearization of clustered polynucleotides by cleaving one or more second strands of double double-stranded polynucleotides immobilized on a solid support comprising azobenzene linker by Na2S2O4. Nucleotides and oligonucleotides comprising a 3? phosphate moiety blocking group, and methods of removing the same using a fluoride reagent are also disclosed.

Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.

Abstract: A beta-adrenergic blocking compound according to the present teachings include compounds having the following structural formula: wherein n is 0 or 1, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a method for recovering protein, which recovers a target protein from a mixture containing the target protein and a material different from the target protein, the method including a dissolution step of dissolving either the target protein or the material by applying pressure while heating to a solution for dissolution containing the mixture and a polar solvent, and a separation step of separating an obtained solution.

Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.

Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.

Abstract: A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants.

Abstract: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.

Abstract: The present invention relates to a long-acting conjugate for brain targeting comprising a peptide for brain targeting and a physiologically active material, and to a long-acting conjugate comprising a physiologically active material with improved durability and stability, which can pass through the blood-brain barrier (BBB) and comprises a physiologically active material. The long-acting conjugate for brain targeting of the present invention comprising a peptide for brain targeting and a physiologically active material can pass through the blood-brain barrier, thus enabling the treatment of diseases associated with brain diseases, and additionally, can maintain the activity of a physiologically active material in vivo and increase its half-life in the blood.

Abstract: A method for preparing AMG 416, or a pharmaceutically acceptable salt thereof, is provided.

Abstract: Peptides having antimicrobial properties are described herein, as are compositions containing such peptides, and methods for using the peptides.

Abstract: The present invention relates to series of peptidomimetic compounds as an inhibitor targeting protein N-terminal methyltransferase pharmacological pathway. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases caused by abnormal protein methyltransferase pathway, including cancer, inflammation, neurodegenerative and cardiovascular diseases, are within the scope of this disclosure.

Abstract: A peptide comprises the sequence: X1-X2-(G or S)-X3-X4-L-(I or M)-X5-X6-G-(V or I)-X7X8 wherein each of X1-X8 is independently any amino acid and is independently present or absent; wherein the peptide has fewer than 30 amino acid residues; and wherein the peptide binds to and inhibits an efflux pump, with the proviso that the peptide does not comprise VVGLALIVAGVVV or VVGLALINAGVVV

Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.

Abstract: The present invention relates to modified peptides, and their use for treating a lupus-related auto-immune or inflammatory disorder, e.g., systemic lupus erythematosus (SLE or “lupus”).

Abstract: Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.

Abstract: The invention relates to protein ligation technologies, purified or recombinant peptides, methods for making peptides and proteins with covalent bonds including reversible covalent bonds such as reversible intermolecular covalent bonds, and uses thereof. In particular, this invention relates to intermolecular ester bonds, particularly reversible ester bonds between the hydroxyl and amide groups of amino acid side chains present in recombinant chimeric peptides and proteins and the use of such peptides and proteins in protein engineering, for example in the preparation of multimeric protein complexes, including functionalised multimeric protein complexes.

Abstract: Disclosed is a method for producing soluble CRM197 protein at high yield by overexpressing the protein in the cytoplasm of E. coli. The method includes a step of culturing recombinant E. coli harboring an expression plasmid carrying a gene sequence coding for a recombinant CRM197 protein under a condition suitable for expression of the recombinant CRM197 protein which has a histidine-tag attached to the C-terminus of CRM197 and a maltose-binding protein (MBP) attached to the N-terminus of CRM197. The method further includes a step of purifying after the culturing, wherein the step of purifying comprises a step of treating with tobacco etch virus (TEV) protease to remove the maltose-binding protein and a step of removing the histidine-tag via histidine-tag affinity chromatography.

Abstract: Mutants of recombinant immunoregulatory protein of Ganoderma lucidum (rLZ-8) and applications thereof are provided. It is found by the present invention that: an anti-EGFR (epidermal growth factor receptor) domain exists in a structure of the rLZ-8; particularly, the domain through positive potential characteristics thereof induces a killing effect to an abnormal EGFR-expressed tumor. Based on the above scientific discovery, with utilizing computational simulation technology, the mutants of the rLZ-8, having better antitumor effects, are obtained.

Abstract: The application generally relates to chloroplast targeting of nuclear-encoded proteins of interest in microalgae. Provided herein are expression cassettes comprising a nucleotide sequence encoding a chloroplast targeting peptide operably linked to a nucleotide sequence encoding a protein of interest, wherein said chloroplast targeting peptide comprises the bipartite targeting sequence of the phosphoribulokinase of Nannochloropsis gaditana (NgPRK BTS). The invention further provides vectors comprising the expression cassettes, and microalgae having stably incorporated or transiently expressed into their nuclear genomes an expression cassette described above. Methods are also provided for the production of a protein of interest in the chloroplast of a microalga, as well as methods for modulating chloroplast pathways.

Abstract: The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.

Abstract: The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

Abstract: The present invention relates to a protein composition formed of dry matter of a dispersion in which a protein is dispersed in a stabilizer solution, in which the stabilizer includes at least one type selected from the group consisting of a catechol-based stabilizer, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 2,6-di-tert-butyl-p-cresol, 2-tert-butyl-4-methoxyphenol, and 6,6?-di-tert-butyl-4,4?-butylidenedi-m-cresol.

Abstract: The present invention provides a mutant beetle luciferase and the like, having mutation in which the amino acid corresponding to valine at position 288 in the amino acid sequence of wild-type Photinus pyralis luciferase is isoleucine, leucine or phenylalanine, mutation in which the amino acid corresponding to leucine at position 376 in the aforementioned sequence is proline, mutation in which the amino acid corresponding to glutamic acid at position 455 in the aforementioned sequence is valine, alanine, serine, leucine, isoleucine or phenylalanine, or mutation in which the amino acid corresponding to glutamic acid at position 488 in the aforementioned sequence is valine, alanine, serine, leucine, isoleucine or phenylalanine, in the amino acid sequence encoding a wild-type beetle luciferase, and characterized in that a luminescence intensity due to a luciferin-luciferase luminescence reaction in a 0.9% by mass NaCl solution is 50% or more of that in a NaCl-free solution.

Abstract: In one aspect, the invention relates to compositions comprising peptides and/or peptidomimetic compounds, methods of making same, pharmaceutical compositions comprising same, and methods of treating various diseases, including, but not limited to, arthritis, obstructive lung disease, psoriasis, asthma, a defect in hematopoiesis, a neoplasia, a fungal infection, a parasitic infection, or an autoimmune disease, such as, but not limited to, rheumatoid arthritis, atopic allergy, anaphylaxis, psoriasis, asthma, lupus erythematosis, a myeloid cell disorder, or a eosinophil cell disorder. In an aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the ST2 and IL33 receptor/cytokine complexes. In a further aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the IL-1R1 and IL-1? receptor/cytokine complexes.

Abstract: Methods of processing protein, methods of generating products with the processed protein, and products comprising and/or made with the processed protein. The methods of processing protein include hydrolyzing the protein with a proteolytic agent such as thermolysin to generate hydrolyzed peptides and, optionally, crosslinking the hydrolyzed peptides with a transglutaminase to generate crosslinked peptides. The methods reduce the allergenicity of allergenicity proteins such as ?-lactoglobulin and casein. The methods of generating products with the processed protein include methods of making foams, emulsions, and/or food products with the processed protein. The products comprising and/or made with the processed protein accordingly include foams, emulsions, and food products. The foams, emulsions, and food products have decreased allergenicity compared to corresponding products made with non-processed proteins.

Abstract: Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

Abstract: An sDR5-Fc recombinant fusion protein having amino acid sequence of SEQ ID NO: 2 and a gene encoding the protein and having a nucleotide sequence as shown in SEQ ID NO: 1 are provided. Further, applications of the protein and the gene in the preparation of medicament for preventing and treating autoimmune hepatitis or drug-induced liver injury are provided.

Abstract: Disclosed herein are compositions and methods for inhibiting collagen production mediated by the Fused in Sarcoma (FUS) ribonucleoprotein. As disclosed herein, the C terminal domain of FUS contains an uncommon nuclear localization sequence (NLS) motif called PY-NLS that binds the nuclear import receptor transportin. Phosphorylation of FUS leads to its association with transportin and nuclear translocation with consequent increased in collagen production. Therefore, disclosed herein is an isolated peptide having a transportin-binding moiety, which inhibits FUS from binding transportin, linked to a membrane translocating motif. These compositions and methods can be used to inhibit FUS-mediated collagen production, and treat fibrotic disease involving FUS-mediated collagen accumulation in kidneys and other organs displaying fibrotic diseases.

Abstract: The present disclosure provides for isolated non-naturally occurring, mutant-human IAPP polypeptides, which are more soluble at neutral pH than the wild-type hIAPP protein. These polypeptides can be formulated or co-formulated at physiological pH, which enable the polypeptides of the instant disclosure to be delivered to a subject in a single injection with an insulin agent. The present disclosure also provides methods and pharmacological compositions for treating an abnormal condition, such as an amyloid-based disease or type-1 diabetes in a subject.

Abstract: The disclosure provides helix grafted proteins, methods of producing helix grafted proteins and methods of use of helix grafted proteins as inhibitors of protein-protein interactions involved in disease pathogenesis.

Abstract: The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to a high mobility group box 1 (HMGB1) polypeptide, wherein in said HMGB1 polypeptide at least one, preferably two, more preferably three, most preferably all four tyrosine residues at positions corresponding to amino acid positions Y109, Y144, Y155 and/or Y162 of human HMGB1 have been exchanged to an amino acid residue independently selected from glutamic acid, glutamine, aspartic acid, asparagine, homoglutamic acid (2-aminohexanedioic acid), and homoglutamine (2,6-diamino-6-oxohexanoic acid). The present invention further relates to a polynucleotide encoding a polypeptide according to the present invention, to a vector comprising said polynucleotide, and to a host cell comprising said polypeptide, said polynucleotide and/or said vector. Also, the present invention relates to methods, kits, and uses related thereto.

Abstract: Described herein are tissue-targeted biologies comprising collagen VII binding domains linked to cytokine binding domains, and their use in suppression of inflammation.

Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a LAG-3 antibody fragment-Fc fusion protein.

Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Abstract: Analogues of an alternatively spliced form of atrial natriuretic peptide (MANP) that exhibit pGC-A gain of function and can be used to treat cardiorenal and metabolic disease are described herein

Abstract: Disclosed herein are expression constructs and methods for producing a protein of interest. According to some examples, an expression construct includes a nucleotide sequence encoding a fusion protein. To produce the protein of interest, the expression construct is transformed into a host cell, which is cultured under conditions that allow the expression of the fusion protein. The fusion protein has at least one expression unit; each expression unit has, sequentially, an affinity tag moiety, a spacer moiety, an enzymatic cleavage site, and a protein of interest moiety. The fusion protein is isolated from the host cell, solubilized, and refolded. The refolded fusion protein is cleaved to release the protein of interest.

Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.

Abstract: Blocking peptides that inhibit FAK or NANOG binding to Cx26, and a method of treating cancer by administering these blocking peptides to a subject in need thereof are described.